ICUI VS LLY Stock Comparison
Performance
ICUI10/100
10/100
ICUI returned -45.55% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
LLY100/100
100/100
LLY returned 68.15% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
ICUI65/100
65/100
5 analysts offer 12-month price targets for ICUI. Together, they have an average target of 190, the most optimistic target put ICUI at 190 within 12-months and the most pessimistic has ICUI at 190.
LLY68/100
68/100
22 analysts offer 12-month price targets for LLY. Together, they have an average target of 391, the most optimistic target put LLY at 673 within 12-months and the most pessimistic has LLY at 236.
Technicals
ICUI25/100
25/100
ICUI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
LLY57/100
57/100
LLY receives a 57 of 100 based on 14 indicators. 7 are bullish, 5 are bearish.
Earnings
ICUI41/100
41/100
ICUI has missed earnings 3 times in the last 20 quarters.
LLY10/100
10/100
LLY has missed earnings 7 times in the last 20 quarters.
Profit
ICUI51/100
51/100
Out of the last 20 quarters, ICUI has had 13 profitable quarters and has increased their profits year over year on 5 of them.
LLY66/100
66/100
Out of the last 20 quarters, LLY has had 19 profitable quarters and has increased their profits year over year on 6 of them.
Volatility
ICUI48/100
48/100
ICUI has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
LLY53/100
53/100
LLY has had a higher than average amount of volatility over the last 12 months giving it a score of 53 of 100.
Dividend
ICUI
"Dividend" not found for ICUI
LLY100/100
100/100
LLY's most recent dividend was $0.57 per share, based on a share price of $588.54. It was a payout ratio of 50.90% compared to their total earnings.
All score calculations are broken down here to help you make more informed investing decisions
ICU Medical Inc Summary
Nasdaq / ICUI
Healthcare
Medical - Instruments & Supplies
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Eli Lilly & Co. Summary
New York Stock Exchange / LLY
Healthcare
Drug Manufacturers - General
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ICUI to other companies in the same or a similar industry.